This study assessed the efficacy, safety, and health-related quality of life (HRQoL) of the treatment regimen of dostarlimab, a programmed death-1 inhibitor, combined with niraparib, a poly (ADP-ribose) polymerase inhibitor, in patients with BRCA wild type (BRCA wt) recurrent platinum-resistant ovarian cancer (PROC) who had previously received bevacizumab treatment. This Phase II, open-label, single-arm, multicenter study, conducted in the USA, enrolled patients with recurrent PROC to receive niraparib and dostarlimab until disease progression or unacceptable toxicity (up to 3 years). A preplanned interim futility analysis was performed after the first 41 patients had undergone ≥1 radiographic evaluation (approximately 9 weeks from the first treatment). The prespecified interim futility criterion was met and the study was therefore terminated. For the 41 patients assessed, the objective response rate (ORR) was 7.3% (95% confidence interval: 1.5–19.9); no patients achieved a complete response, 3 patients (7.3%) achieved a partial response (duration of response; 3.0, 3.8, and 9.2 months, respectively) , and 9 patients (22.0%) had stable disease. In total, 39 patients (95.1%) experienced a treatment-related adverse event, but no new safety issues were observed. HRQoL, assessed using FOSI, or Functional Assessment of Cancer Therapy – Ovarian Symptom Index scores, worsened over time compared with baseline scores. The study was terminated due to the observed ORR at the interim futility analysis. This highlights a need for effective therapies in treating patients with recurrent BRCA wt PROC. [Display omitted] • Overall response rate did not improve with niraparib and dostarlimab in recurrent BRCA wt platinum-resistant ovarian cancer (124/125). • Low objective response rate versus standard of care triggered prespecified futility criteria and early study termination (122/125). • No new safety signals were reported for niraparib and dostarlimab combination therapy (87/125). • Health-related quality of life measures worsened over time from baseline, with no control group for comparison (112/125). [ABSTRACT FROM AUTHOR]